Cordex Pharma, Inc. (Cordex) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine 5'-triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders.

 

Cordex is developing a portfolio of therapeutic and diagnostic products, two of which are in advanced stages of clinical studies. Cordex is now preparing for a pivotal Phase 3 clinical trial with ATPace as an anti-arrhythmic drug for the treatment of paroxysmal supraventricular tachycardia and a proof-of-concept Phase 2 clinical trial with CDP-1050 for the treatment of heart failure. In addition, Cordex has a preclinical drug discovery program aimed at a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease and chronic cough.

Copyright © 2009 Cordex Pharma, Inc. 1999-2009 All rights reserved.

 

Recent News

· Cordex Completes Production of ATPace^TM Clinical Trial Material

· Cordex Signs European Development Partnership for ATPotent^TM Sperm Motility Drug

· Cordex Receives Special Protocol Assessment Approval from FDA for ATPace^TM

· Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers

· Cordex Pharma Files ATPace Formulation Patent

· Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures

· Cordex Pharma Submits to the FDA an Amended Special Protocol Assessment for ATPace

· Cordex Pharma Sets Fourth Quarter 2008 Program Update Call

· Cordex Pharma Forms Heart Failure Medical Advisory Board

· Duska Therapeutics Completes Corporate Name Change to Cordex Pharma

· Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product

· Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program

· Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant

· Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins

info@cordexpharma.com

Duska Therapeutics, Inc. is the former name of Cordex Pharma, Inc